Copyright
©The Author(s) 2017.
World J Gastrointest Pharmacol Ther. Aug 6, 2017; 8(3): 155-161
Published online Aug 6, 2017. doi: 10.4292/wjgpt.v8.i3.155
Published online Aug 6, 2017. doi: 10.4292/wjgpt.v8.i3.155
Table 1 Management of secondary loss of response
No/low antibody level | High antibody level | |
Low drug level | Increase drug dose | Change therapy (within class or alternate class) |
Normal/high drug level | Change therapy (alternate class) | (Not clinically relevant scenario) |
- Citation: Kothari MM, Nguyen DL, Parekh NK. Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature. World J Gastrointest Pharmacol Ther 2017; 8(3): 155-161
- URL: https://www.wjgnet.com/2150-5349/full/v8/i3/155.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v8.i3.155